Merck & Co Inc
MRK90.909USD
+4.159+4.79%
Market hours （ET）Quotes delayed by 15 min
226.12BMarket Cap
11.88P/E TTM
More Details of Merck & Co Inc Company
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
Merck & Co Inc Info
Ticker SymbolMRK
Company nameMerck & Co Inc
IPO dateJan 01, 1941
CEOMr. Robert M. (Rob) Davis
Number of employees75000
Security typeOrdinary Share
Fiscal year-endJan 01
Address126 East Lincoln Avenue
CityRAHWAY
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code07065
Phone19087404000
Websitehttps://www.merck.com/
Ticker SymbolMRK
IPO dateJan 01, 1941
CEOMr. Robert M. (Rob) Davis
Company Executives of Merck & Co Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
Other
4.47B
28.27%
By RegionUSD
Name
Revenue
Proportion
United States
8.84B
55.90%
Europe, Middle East and Africa
3.66B
23.15%
Latin America
859.00M
5.43%
Asia Pacific (Other than China and Japan)
785.00M
4.97%
Japan
626.00M
3.96%
Other
1.04B
6.59%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
Other
4.47B
28.27%
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.75%
State Street Investment Management (US)
4.77%
Wellington Management Company, LLP
3.10%
Geode Capital Management, L.L.C.
2.38%
Other
73.89%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.75%
State Street Investment Management (US)
4.77%
Wellington Management Company, LLP
3.10%
Geode Capital Management, L.L.C.
2.38%
Other
73.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.33%
Investment Advisor/Hedge Fund
27.33%
Research Firm
3.24%
Pension Fund
2.47%
Bank and Trust
2.34%
Sovereign Wealth Fund
1.56%
Hedge Fund
1.38%
Insurance Company
0.71%
Family Office
0.12%
Other
18.53%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
251.75M
10.08%
+356.59K
+0.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.78M
5.72%
-4.51M
-3.06%
Jun 30, 2025
State Street Investment Management (US)
118.49M
4.74%
-2.04M
-1.69%
Jun 30, 2025
Wellington Management Company, LLP
76.86M
3.08%
-4.81M
-5.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.95M
2.36%
-704.59K
-1.18%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
53.87M
2.16%
+4.64M
+9.42%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
28.48M
1.14%
+229.47K
+0.81%
Jun 30, 2025
Fisher Investments
25.01M
1%
+567.90K
+2.32%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
22.79M
0.91%
+764.14K
+3.47%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
FT Vest DJIA Dogs 10 Target Income ETF
7.58%
VanEck Pharmaceutical ETF
7.44%
First Trust NASDAQ Pharmaceuticals ETF
7.32%
Coastal Compass 100 ETF
7.15%
Invesco Dow Jones Industrial Average Dividend ETF
6.85%
iShares ESG Aware MSCI USA Value ETF
5.44%
First Trust Morningstar Dividend Leaders Index Fund
5.03%
Franklin Income Focus ETF
4.92%
Invesco Pharmaceuticals ETF
4.84%
VanEck Morningstar Wide Moat Value ETF
4.6%
View more
FT Vest DJIA Dogs 10 Target Income ETF
Proportion7.58%
VanEck Pharmaceutical ETF
Proportion7.44%
First Trust NASDAQ Pharmaceuticals ETF
Proportion7.32%
Coastal Compass 100 ETF
Proportion7.15%
Invesco Dow Jones Industrial Average Dividend ETF
Proportion6.85%
iShares ESG Aware MSCI USA Value ETF
Proportion5.44%
First Trust Morningstar Dividend Leaders Index Fund
Proportion5.03%
Franklin Income Focus ETF
Proportion4.92%
Invesco Pharmaceuticals ETF
Proportion4.84%
VanEck Morningstar Wide Moat Value ETF
Proportion4.6%
Dividend
A total of
35.12B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
